Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study Identifier
M03-658
CT.gov Identifier
EudraCT Identifier
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Results Available
Scientific Result Summary
Available Language(s): English
Study Details
Medical Condition
Study Drug
Phase
Phase 3
Sex
Female & Male
Age
18+ years
Protocol Summary
The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab
treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate
the effectiveness of adalimumab retreatment in participants who had therapeutic response to
adalimumab and were then withdrawn from adalimumab treatment.
Study Locations
Location
Status
Location
Site Reference ID/Investigator# 1263
Birmingham, Alabama, United States, 35205
Status
Not applicable
Location
Site Reference ID/Investigator# 1259
Buckner 13075 PI, Alabama, United States, 35233
Status
Not applicable
Location
Site Reference ID/Investigator# 2427
Scottsdale, Arizona, United States, 85251
Status
Not applicable
Location
Site Reference ID/Investigator# 2433
Tucson, Arizona, United States, 85710
Status
Not applicable
Location
Site Reference ID/Investigator# 100
Little Rock, Arkansas, United States, 72205
Status
Not applicable
Location
Site Reference ID/Investigator# 1798
Bakersfield, California, United States, 93309
Status
Not applicable
Showing {first} - {last} of {total} Results